ライフサイエンスコーパス: bleed

1 occurred during the study (gastrointestinal bleed).

2 events (155 with moderate and 80 with severe bleeding).

3 .3% (0.1% with moderate and 0.2% with severe bleeding).

4 uids, or a case with diarrhoea, vomiting, or bleeding).

5 at the coexistent coagulopathy could promote bleeding.

6 y intervention without an increase in severe bleeding.

7 cted and assessed for consistency and occult bleeding.

8 (ITP) increased platelet counts and reduced bleeding.

9 ntracranial bleeding or other critical organ bleeding.

10 ion on experimental thrombus dissolution and bleeding.

11 systemic anticoagulation is difficult due to bleeding.

12 We also assessed variceal and nonvariceal bleeding.

13 sis In Myocardial Infarction major and minor bleeding.

14 ge or gastrointestinal, urogenital, or other bleeding.

15 cting the location of acute gastrointestinal bleeding.

16 defined a new HCA subgroup at a high risk of bleeding.

17 The primary safety end point was major bleeding.

18 d antithrombotic efficacy without increasing bleeding.

19 enesis, gastrointestinal angiodysplasia, and bleeding.

20 ts on NOACs who bleed or who are at risk for bleeding.

21 old but does not increase the risk of major bleeding.

22 vents after coronary stenting, but increases bleeding.

23 ic tumour excision to reduce intra-operative bleeding.

24 age, were used to estimate rates of total GI bleeding.

25 ant for predicting oral hygiene and gingival bleeding.

26 e segment with a history of painless vaginal bleeding.

27 t degrade fibrinogen or enhance experimental bleeding.

28 with suspected lower gastrointestinal tract bleeding.

29 s 4.3% for MI, 0.9% for stroke, and 5.0% for bleeding.

30 nor bleedings and less incidence of variceal bleeding.

31 ays and the primary safety outcome was major bleeding.

32 ial modifiable risk factor for perioperative bleeding.

33 s risk of thrombosis and the severity of the bleeding.

34 , blood transfusion, and hospitalization for bleeding.

35 stroke (3.3% versus 2.2%), life-threatening bleeding (1.1% versus 1.1%), and major vascular complica

36 nfarction (2.9% versus 0.2%; P<0.001), major bleeding (14.0% versus 0.9%; P<0.001), blood transfusion

37 LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or hernia-related complica

38 sus 42.1%; hazard ratio, 1.11; P<0.001), and bleeding (23.1% versus 19.7%; hazard ratio, 1.18; P<0.00

39 2.27-4.24; p<0.0001), particularly for fatal bleeds (5.53, 2.65-11.54; p<0.0001), and was sustained d

40 by men (582 [67.3%]), and for intraoperative bleeding (544 [62.9%]).

41 Respiratory (14.7%), infections (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%)

42 lined, including mortality (3.57% to 2.15%), bleeding (9.56% to 5.08%), vascular complications (6.11%

43 a significantly greater risk of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1

44 cation, which was a composite of access-site bleeding, access-site hematoma, retroperitoneal bleeding

45 isease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complica

46 y was associated with more, and more severe, bleeding (adjusted cOR 2.54, 95% CI 2.05-3.16, p<0.0001)

47 e interval, 1.42-3.59; P=0.0006), but not of bleeding (adjusted hazard ratio, 0.99; 95% confidence in

48 emonstrated by the complete normalization of bleeding after a severe tail clip injury in these mice.

49 ncluded rates of VTE and clinically relevant bleeding after surgical procedures, stratified by Caprin

50 e hazard of death, myocardial infarction, or bleeding (AKIN 1: hazard ratio [HR], 1.53; confidence in

51 Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but

52 One-year mortality was 27.1% for a major bleed and 26.3% for a thrombotic event.

53 All patients had a hospitalization for GI bleed and received octreotide after discharge.

54 mic embolic events and significantly reduced bleeding and cardiovascular mortality.

55 evated hematocrit is associated with reduced bleeding and increased thrombosis risk in humans.

56 rations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short

57 Bivalirudin has been associated with reduced bleeding and mortality during primary percutaneous coron

58 Anticoagulant therapy-associated bleeding and pathological thrombosis pose serious risks

59 dentified 2 unrelated families in the BRIDGE Bleeding and Platelet Disorders (BPD) collection who car

60 ty, we affirm the tradeoff between increased bleeding and reduced myocardial infarctions with prolong

61 test the hypothesis that laropiprant limits bleeding and rescues the brain from ICH.

62 Knowledge about risk of bleeding and short-term thrombotic risk resides in many

63 onin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between

64 Strategies to reduce the daily risk of bleeding and thrombosis, and different thresholds for tr

65 ac failure in children but is complicated by bleeding and thrombosis.

66 ted to the hospital are at increased risk of bleeding and thrombosis.

67 ened and stiffened clots are associated with bleeding and thrombotic disorders.

68 Bleeding and vascular complications, using permeable nit

69 valves had a higher cumulative incidence of bleeding and, in some age groups, stroke than did recipi

70 They can be unsightly, spontaneously bleed, and cause irritation to patients.

71 ) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

72 Age <5 years, bleeding, and high viral loads were poor prognostic indi

73 rtality, renal failure, atrial fibrillation, bleeding, and length of intensive care unit stay.

74 reported relative risks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy c

75 reported incidence rates of thrombosis, any bleeding, and major bleeding without antiplatelet therap

76 ssociated with risk factors, histopathology, bleeding, and malignant transformation.

77 troke, intracranial hemorrhage, extracranial bleeding, and myocardial infarction identified from hosp

78 In patients with overt gastrointestinal bleeding, and negative findings on esophagogastroduodeno

79 nd point analyses of vascular complications, bleeding, and new pacemaker/defibrillator implantation d

80 TIPS volume of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent ris

81 hs, artificial ventilation, intraventricular bleeding, and other perinatal adverse events.

82 reased risk of death, myocardial infarction, bleeding, and recurrent renal injury after discharge.

83 testinal bleeding, with all gastrointestinal bleeding as a secondary outcome.

84 s had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor.

85 tional Society of Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH BAT) confirmed significan

86 Development and use of bleeding assessment tools allows for improved stratifica

87 one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable spleen of at

88 With the exception of minor bleeding at the injection site in a few animals injected

89 effect of anticoagulant therapy on menstrual bleeding at the time of treatment initiation.

90 hose undergoing transfemoral PCI, whereas no bleeding benefit was observed for those treated with tra

91 and also had an indirect effect on gingival bleeding (beta = 0.011; P = 0.05).

92 ively associated with the extent of gingival bleeding (beta = 0.24; P = 0.01).

93 proportions of patients with major or minor bleeding between groups that did vs did not receive anti

94 tality and rates of reoperation, stroke, and bleeding between inverse-probability-weighted cohorts of

95 mia significantly exceeded the daily risk of bleeding beyond 30 days, supporting the use of intensifi

96 (1) To measure the incidence of bleeding (blood loss requiring transfusion or intracrani

97 ng aorta or aortic arch) with intraoperative bleeding (blood volume between 60 and 250 mL suctioned f

98 Safety outcomes included major bleeding, blood transfusion, and hospitalization for ble

99 inolytic therapy increased the risk of major bleeding by 1.27-8.82-times compared with accelerated in

100 nticoagulants reduce the risk of intraocular bleeding by approximately one-fifth compared with warfar

101 bitors (PPIs) reduces upper gastrointestinal bleeds by 70-90%, uptake is low and guidelines are confl

102 ria ohridella, the bacterial causal agent of bleeding canker disease Pseudomonas syringae pv aesculi,

103 istory predictors of leaf miner infestation, bleeding canker, or coinfection.

104 toma expansion was tested by an in vivo tail bleeding cessation method and an ex vivo coagulation met

105 nts in this study experienced a recurrent GI bleed compared with a matched historical control group t

106 sociated with increased incidence rate of GI bleeding compared with non-exposed period among naive da

107 ban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%]

108 d risk of all severities of gastrointestinal bleeding compared with warfarin (0.25 [0.07-0.76]) or da

109 nsplant recipient and resulted in death from bleeding complications 18 days posttransplantation.

110 Bleeding complications arising from trauma, surgery, and

111 e with heart failure signs at admission, and bleeding complications increased with higher MI-ERR.

112 Bleeding complications occurred in alternatively anticoa

113 and those with non-healing wounds or active bleeding conditions were ineligible.

114 ntary test in patients with gastrointestinal bleeding, Crohn's disease, or celiac disease, who have h

115 Major bleeding, defined as hospitalization or emergency depart

116 Upper gastrointestinal bleeding developed in 6.1% of patients in the pantoprazo

117 Bleeding differences were, in part, explained by the gre

118 ts and actively block FVIII activity, making bleeding difficult to control and prevent.

119 ay platelet syndrome (GPS), a rare recessive bleeding disorder characterized by platelets lacking alp

120 ciency of factor X (F10) in humans is a rare bleeding disorder with a heterogeneous phenotype and lim

121 d disease (VWD) is the most common inherited bleeding disorder, yet diagnosis and management remain c

122 or hepatitis C viral infection, and a known bleeding disorder.

123 ent in a subset of patients with undiagnosed bleeding disorders, and therefore may function as a clin

124 and therapeutics for affected patients with bleeding disorders.

125 d tool for the prediction of out-of-hospital bleeding during DAPT.

126 Obstetrics complications and excessive bleeding during delivery contributed to nearly 30% of th

127 of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regar

128 ffer the promise to improve the treatment of bleeding episodes in patients with inhibitor-complicated

129 llow-up, 21 patients had at least one severe bleeding event (WHO bleeding score >/=2).

130 The cumulative incidence of death after a bleeding event among the total randomized study populati

131 (95% CI, 0.19 to 0.30) for any hospitalized bleeding event and 0.15 (95% CI, 0.11 to 0.20) for moder

132 The annualized mortality rate after a bleeding event was 21.5 (95% CI, 15.4-29.1) per 100 pers

133 stroke), and 232 individuals (2.0%) had 235 bleeding events (155 with moderate and 80 with severe bl

134 (1582 [50%] aged >/=75 years) had 405 first bleeding events (n=218 gastrointestinal, n=45 intracrani

135 The risk of recurrent ischemic and bleeding events after primary percutaneous coronary inte

136 GI bleeding events among patient aged 75 years or older tak

137 life-threatening bleeding or major or minor bleeding events in patients with ipsilateral stenosis in

138 f GI surgery does not significantly increase bleeding events in the month after surgery.

139 s; and apixaban, 12886 patients), 4770 major bleeding events occurred during 447037 person-quarters w

140 ine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were

141 claims-identified and physician-adjudicated bleeding events was poor, with a kappa of 0.24 (95% CI,

142 Fourteen patients (38%) experienced bleeding events, of which six (16%) were associated with

143 tive in raising platelet counts and reducing bleeding events.

144 Although the rates for bleeding exceeded those for ischemia within 30 days, the

145 d death, all-cause death, and post-procedure bleeding favored LAAC (HR: 0.20; p = 0.0022; HR: 0.45; p

146 ng microsphere used to reduce intraoperative bleeding for head and neck tumours.

147 comes, including mortality, readmission, and bleeding, for patients with PAD compared with those with

148 ty, type 2 diabetes, gastrointestinal ulcers/bleeds, fractures, and cataracts (odds, 1.21-1.44 depend

149 hylaxis with octreotide after their index GI bleed from 2009 to 2015.

150 e 5: Patients at high risk for ulcer-related bleeding from NSAIDs should take a PPI if they continue

151 stimates of the association between gingival bleeding (GB) and oral health-related quality of life (O

152 h was associated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence interval: 1

153 Therefore, stoppage of bleeding (hemostasis) is of paramount clinical significa

154 ation (ascites, encephalopathy, and variceal bleeding), hepatocellular carcinoma, liver transplantati

155 ignificantly more bleeders had a previous GI bleeding history before left ventricular assist device p

156 ts treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; P=0.021) bu

157 nteraction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patients wit

158 s the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront compli

159 r major bleeding, the addition of vWF to HAS-BLED improved the c-index but not IDI or NRI.

160 Quantification of the column bleed in trapped samples, however, is extremely challeng

161 d systemic infection in 11, gastrointestinal bleeding in 1, and severe electrolyte imbalance in 1, al

162 schemic attack in 1 patient, reoperation for bleeding in 2 patients, and median length of stay was 4

163 stem cells have been shown to control joint bleeding in animal models of hemophilia.

164 tatistically significant difference in major bleeding in apixaban-treated patients.

165 PI use was associated with increased risk of bleeding in both treatment arms.

166 longer DAPT duration significantly increased bleeding in patients at high risk (score >/=25), but not

167 Antifibrinolytics reduce death from bleeding in trauma and post-partum haemorrhage.

168 jor bleeding was unrelated to age, but major bleeding increased steeply with age (>/=75 years hazard

169 ollowing parameters were evaluated: gingival bleeding index (GBI), probing depth (PD), myeloperoxidas

170 and 9 months; they included modified sulcus bleeding index (mSBI), plaque index (PI), probing depth

171 included plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), and clinical

172 Acute lower gastrointestinal bleeding is a common reason for emergency hospital admis

173 Acute upper gastrointestinal bleeding is a leading indication for red blood cell (RBC

174 Perioperative bleeding is a potentially devastating complication in ne

175 re Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE]; NCT01623180).

176 ES improved their predictive value for major bleeding leading to improved clinical usefulness compare

177 the assessment of the effectiveness of major bleeding management.

178 the UHCA, of which 64.7% presented clinical bleeding manifestations.

179 use of postpancreatectomy sepsis (n = 11) or bleeding (n = 11).

180 Major bleeding occurred in 36 patients (6.9%) in the edoxaban

181 Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivar

182 GI bleeding occurred more frequently in patients given riva

183 ndex for out-of-hospital TIMI major or minor bleeding of 0.73 (95% CI 0.61-0.85) in the derivation co

184 ontal outcomes were percentage of teeth with bleeding on probing (BOP) and combination of BOP and att

185 were plaque index (PI), gingival index (GI), bleeding on probing (BOP), PD, gingival crevicular fluid

186 s of > 2 mm, probing depth (PD) >/=5 mm with bleeding on probing (BOP).

187 PD], plaque index [PI], gingival index [GI], bleeding on probing [BOP], and clinical attachment level

188 t soft tissue parameters (plaque index [PI], bleeding on probing [BOP], and probing depth [PD] >/=4 m

189 95% CI, 0.11 to 0.20) for moderate or severe bleeding on the GUSTO scale.

190 ainty on how to manage patients on NOACs who bleed or who are at risk for bleeding.

191 TIPS) correlates with the absence of further bleeding or ascites at follow-up examinations of patient

192 marrow hematopoiesis and EMH in response to bleeding or G-CSF treatment.

193 included IVF- and LD-related safety, such as bleeding or infections, and functional outcome at 90 and

194 rences in the proportion of life-threatening bleeding or major or minor bleeding events in patients w

195 was no significant increase in intracranial bleeding or other critical organ bleeding.

196 rom 2042 cases in pedigrees with unexplained bleeding or platelet disorders to data from 5422 control

197 The first 3 months after a major bleeding or surgical procedure were excluded from the ti

198 5) and weak evidence of an increase in major bleeding (OR, 1.66; 95% credible intervals, 0.89-3.09) a

199 eding, access-site hematoma, retroperitoneal bleeding, or any vascular complication requiring interve

200 vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome.

201 f 4 weeks: platelet transfusion, symptomatic bleeding, or platelet count of less than 10 x 10(9) per

202 combining proportion of teeth with calculus, bleeding, or pocket with income; number of lost teeth; s

203 ne disabling or fatal upper gastrointestinal bleed over 5 years fell from 338 for individuals younger

204 We did not detect an increased risk of GI bleeding over dabigatran vs warfarin risk period.

205 02), vascular complications (p < 0.003), and bleeding (p < 0.001) but was not associated with stroke

206 xamic acid, with no heterogeneity by site of bleeding (p=0.5956).

207 TRUS-biopsy can cause side-effects including bleeding, pain, and infection.

208 ctron scattering at the device edge tends to bleed parasitic states into the gap, but the resulting p

209 arfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality

210 ed importance in diagnosing gastrointestinal bleeding, particularly in hemodynamically unstable patie

211 ive PFD associated with a moderate or severe bleeding phenotype and complex defects in platelet aggre

212 ssment Tool (ISTH BAT) confirmed significant bleeding phenotypes in the majority of LoVIC patients.

213 = 0.81), as was increase in moderate/severe bleeding (pinteraction = 0.44).

214 ed ligand binding-site antagonist results in bleeding, possibly owing to the important role of PAR1 a

215 Calculus, pocket, or bleeding presence at age 24 years separately presented f

216 non-steroidal anti-inflammatory drug (NSAID) bleeding prophylaxis.

217 and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perfora

218 A trend toward an increased bleeding rate at presentation was observed in HHT (p = 0

219 articipants, 28 to 78 weeks), the annualized bleeding rate was significantly reduced (mean rate, 11.1

220 h kidney disease had higher gastrointestinal bleeding rates with dabigatran.

221 use was associated with substantially higher bleeding rates, regardless of the randomization to cangr

222 ved octreotide, to provide a context for the bleeding rates.

223 a platelet transfusion at the first sign of bleeding, rather than prophylactically.

224 revious admission for lower gastrointestinal bleeding, rectal examination findings, heart rate, systo

225 with octreotide had a significantly lower GI bleed recurrence compared with historical controls not t

226 nt factor 3 (C3) deficiency causes prolonged bleeding, reduced thrombus incidence, thrombus size, fib

227 cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss.

228 Before GPI adjustment, bleeding reductions with bivalirudin ranged from 2.04% (

229 coagulation to devise whole-body fasting and bleeding regimens to prevent rupture.

230 rently identified by default, a high risk of bleeding remains a clinical issue.

231 Bleeding remains a significant problem for many thromboc

232 me (disability or death), and time course of bleeding requiring medical attention by face-to-face fol

233 associated with malignant transformation and bleeding, respectively.

234 the benefit of anticoagulation outweighs the bleeding risk (net clinical benefit) has been shown to b

235 Uncertainty remains as to which markers of bleeding risk are independent predictors.

236 Guidelines support weighting bleeding risk before the selection of treatment duration

237 imilar ischemic risk and lower risk-adjusted bleeding risk compared with clopidogrel-GPIs.

238 over BMS were maintained for 2 years in high bleeding risk patients.

239 ratified by trial, and developed a numerical bleeding risk score.

240 Bleeding risk with vitamin K antagonists (VKAs) is close

241 ents with severe kidney disease may increase bleeding risk, whereas dose reductions without a firm in

242 ivator) therapy may be required, despite its bleeding risk.

243 -6 months) treatment in relation to baseline bleeding risk.

244 risk of MI but was associated with increased bleeding risk.

245 To compare the ischemic and bleeding risks associated with glycoprotein IIb/IIIa inh

246 Safety was assessed by 3 validated bleeding scales (Global Use of Strategies to Open Occlud

247 had at least one severe bleeding event (WHO bleeding score >/=2).

248 ween each HL measure versus number of teeth, bleeding score, plaque score, and periodontal severity w

249 e-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI majo

250 atients with cirrhosis and previous variceal bleeding stratified by cirrhosis severity (Child A versu

251 Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical

252 sis to reduce the frequent adverse events of bleeding, stroke, and pump thrombosis; and they must bec

253 device implantation with no deaths, strokes, bleeding, tamponade, or valve reintervention.

254 d with peptic ulcer disease and an increased bleeding tendency.

255 For major bleeding, the addition of vWF to HAS-BLED improved the c

256 crease in the risk of upper gastrointestinal bleeding; the effect of proton pump inhibitors on ventil

257 studies (257 patients) reported rates of any bleeding; there was no difference in the proportions of

258 rce and the cause of active gastrointestinal bleeding, thereby expediting treatment initiation.

259 For "any bleeding," this was lower for treatment with apixaban an

260 on of HRAE (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neur

261 ve shown that platelets prevent inflammatory bleeding through (hem) immunoreceptor tyrosine-based act

262 440 nm wavelength and we alleviate spectral bleed-through associated limitations with the very dim-f

263 Tail bleeding time was prolonged in DREAM KO control mice, bu

264 The tail bleeding time was significantly lower in laropiprant gro

265 in those patients with perforation including bleeding, transfusion, myocardial infarction, and death.

266 Upper gastrointestinal bleeding (UGIB) is a common gastrointestinal emergency,

267 deleterious effect on the extent of gingival bleeding via a worse oral hygiene status of children, bu

268 Vascular and bleeding volume-outcome associations were nonlinear with

269 e effect of cangrelor on ischemic events and bleeding was analyzed in the subgroup of patients with a

270 Bleeding was associated with higher mortality (adjusted

271 m any cause, myocardial infarction, or major bleeding was not lower among those who received bivaliru

272 Bleeding was rare at presentation (5%) and manifested su

273 No major bleeding was recorded, and no patient died during the st

274 ders, the incidence rate of gastrointestinal bleeding was similar during dabigatran risk period and n

275 Risk of non-major bleeding was unrelated to age, but major bleeding increa

276 In all patients, bleeding was verified by means of other methods such as

277 death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years 1, 2,

278 (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and rand

279 nt admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivaroxaban:

280 revascularization (RR); and (4) hospitalized bleeding were compared using Cox proportional hazards re

281 Reductions in bleeding were largest among those undergoing transfemora

282 Data on intraocular bleeding were pooled using inverse-variance, weighted, f

283 ed with thrombosis but result in less severe bleeding when co-inherited with hemophilia.

284 gnificantly increased the risk for any major bleeding when compared with warfarin (hazard ratio, 1.20

285 associated with a similar risk of any major bleeding when compared with warfarin and dabigatran.

286 year after MI were lower for MI, stroke, and bleeding when medical claims were used to identify event

287 octreotide prophylaxis developed another GI bleed, whereas 39 (76%) did not.

288 ents) reported rates of spontaneous variceal bleeding, which occurred in a significantly lower propor

289 dentify patients with lower gastrointestinal bleeding who are suitable for safe outpatient management

290 dentify patients with lower gastrointestinal bleeding who could safely avoid hospital admission.

291 isks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy compared with none ra

292 tes of GUSTO-defined severe/life-threatening bleeding with cangrelor alone compared with clopidogrel-

293 nificant difference in GUSTO moderate/severe bleeding with cangrelor versus clopidogrel (1.1% versus

294 o increase in risk of major gastrointestinal bleeding with direct oral anticoagulants compared with w

295 To characterize the risk of intraocular bleeding with novel oral anticoagulants compared with wa

296 It is unclear if the risk of intraocular bleeding with novel oral anticoagulants differs compared

297 Comparably lower risks of intraocular bleeding with novel oral anticoagulants were seen in sub

298 was the incidence of major gastrointestinal bleeding, with all gastrointestinal bleeding as a second

299 symptomatic venous thromboembolism and major bleeding within 3 months after the procedure.

300 rates of thrombosis, any bleeding, and major bleeding without antiplatelet therapy ranged from 5 to 1